Reshma Kewalramani, M.D., FASN, is the Chief Executive Officer and President at Vertex. Dr. Kewalramani has dedicated her career to improving the lives of patients, including the last 15+ years through the development of new medicines. She joined Vertex in 2017 and was previously the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs. During that time, Vertex made remarkable progress to bring new medicines to more cystic fibrosis (CF) patients around the world, including the approval of SYMDEKO/SYMKEVI and the rapid approval of TRIKAFTA to potentially treat up to 90% of all CF patients. Under Dr. Kewalramani’s leadership, Vertex also advanced several programs outside of CF into the clinic, including alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, sickle cell disease and beta-thalassemia.
Prior to Vertex, Dr. Kewalramani spent more than 12 years at Amgen where she held a variety of roles across Research and Development, including as Vice President, Global Clinical Development, Nephrology & Metabolic Therapeutic Area and Vice President, U.S. Medical Organization, a group she established and grew to assume responsibility for the full portfolio of molecules.
Dr. Kewalramani is passionate about developing and supporting the next generation of scientists and giving back to her community. She is a member of the board of directors of the Biomedical Science Careers Program, an organization dedicated to supporting underrepresented students to pursue a career in STEM, and RIZE Massachusetts, a nonprofit foundation focused on ending the opioid epidemic. She is also a member of Boston University School of Medicine Dean’s Advisory Board. She is a Fellow of the American Society of Nephrology and was on the inaugural Board of Directors of the Kidney Health Initiative.
She is the recipient of the American College of Physicians Associates Council Award, the American Medical Women's Association Janet M. Glasgow Memorial Achievement Citation, and the Harvard Medical School Excellence in Teaching Award. In 2019, she was the recipient of the TiE Boston Healthcare Leadership Award and named one of Boston Business Journal’s Power 50.
Dr. Kewalramani completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. Dr. Kewalramani received her medical degree, with honors, from the seven-year medicine program at the Boston University School of Medicine and completed the General Management Program at Harvard Business School.
What is Reshma Kewalramani's net worth?
The estimated net worth of Reshma Kewalramani is at least $42.11 million as of July 22nd, 2024. Dr. Kewalramani owns 106,172 shares of Vertex Pharmaceuticals stock worth more than $42,112,062 as of December 20th. This net worth evaluation does not reflect any other investments that Dr. Kewalramani may own. Additionally, Dr. Kewalramani receives an annual salary of $5,590,000.00 as CEO at Vertex Pharmaceuticals. Learn More about Reshma Kewalramani's net worth.
How old is Reshma Kewalramani?
What is Reshma Kewalramani's salary?
How do I contact Reshma Kewalramani?
Has Reshma Kewalramani been buying or selling shares of Vertex Pharmaceuticals?
Reshma Kewalramani has not been actively trading shares of Vertex Pharmaceuticals during the last ninety days. Most recently, Reshma Kewalramani sold 15,202 shares of the business's stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $497.00, for a transaction totalling $7,555,394.00. Following the completion of the sale, the chief executive officer now directly owns 106,172 shares of the company's stock, valued at $52,767,484. Learn More on Reshma Kewalramani's trading history.
Who are Vertex Pharmaceuticals' active insiders?
Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?
During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company.
Learn More about insider trades at Vertex Pharmaceuticals. Information on this page was last updated on 11/15/2024.